Migraine sufferers will have to find an alternative due to a shortage of Excedrin pain relief medicine that was caused by a temporary halt in production and distribution by pharmaceutical company GlaxoSmithKline.
“Patient safety and product quality are our utmost priorities at GSK. Through routine quality control and assurance measures, we discovered inconsistencies in how we transfer and weigh ingredients for Excedrin Extra Strength Caplets and Geltabs and Excedrin Migraine Caplets and Geltabs,” the company said in a statement released to Channel 9 WSYR.
“Based on the available data, GSK believes that the product, does not pose a safety risk to consumers. However, as a precautionary measure, GSK Consumer Healthcare has voluntarily implemented a discontinuation of production and distribution.”